OncLive SOSS

Authors

Gregory M. Springett, MD, PhD

Latest:

Immunotherapy Combined With Chemotherapy for Pancreatic Cancer: A Game Changer?

This article reviews up-to-date clinical studies combining chemotherapy with immunotherapy; it also explains the rationale for this combination in treatment of pancreatic cancer.

Gregory Riely, MD

Latest:

Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs

Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.

Gregory Springett MD PhD

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Gregory Vidal, MD, PhD

Latest:

Patient-Centered Decisions and Evolving Treatment Landscape for HER2+ Metastatic Breast Cancer

Panelists discuss how treatment decisions in later-line settings should incorporate clinical trials, patient preferences regarding quality of life, medication scheduling, financial considerations, and previous adverse effect experiences, while also addressing special considerations for brain metastases.

Gregory W. Randolph, MD

Latest:

Dr. Randolph on Future Treatment Approaches in Thyroid Cancer

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future methods of treating patients with thyroid cancer.

Gregory Zagaja, MD

Latest:

Dr. Zagaja on Major Benefit With Prostatectomy

Gregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.

Grzegorz S. Nowakowski, MD

Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center

Latest:

Dr Nowakowski on the FDA Approval of Brentuximab Vedotin for R/R LBCL

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in relapsed/refractory LBCL.

Grzegorz S. Nowakowski, MD, Mayo Clinic

Latest:

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Guillem Argiles, MD

Latest:

Dr. Argiles Discusses the Role of Immunotherapy in CRC

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer.

Guillermo Garcia-Manero, MD

Guillermo Garcia-Manero, MD, is director of the Fellowship Program, the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, deputy chair of Translational Research, a professor, and chief of the Section of Myelodysplastic Syndromes in the Department of Leukemia, as well as leader of the MDS/AML Moon Shot Program at The University of Texas MD Anderson Cancer Center in Houston.

Latest:

Key Areas of Ongoing Research in MDS

Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.

Guiseppe Visani, MD

Latest:

Dr. Visani on Tosedostat and Cytarbine in Elderly Patients With AML

Guiseppe Visani, MD, director, Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy, discusses a phase II study examining the efficacy of tosedostat plus low-dose cytarabine in elderly patients with acute myeloid leukemia.

Gulam A. Manji, MD, PhD

Latest:

Dr. Manji on Lack of Actionable Targets in Patients with Colorectal Cancer

Gulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.

Gunter von Minckwitz, MD

Latest:

Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer

Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

Gunter von Minckwitz, MD, PhD

Latest:

Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.

Guru P. Sonpavde, MD

Guru P. Sonpavde, MD, is the medical director for Genitourinary (GU) Oncology, assistant director of the Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at AdventHealth Cancer Institute.

Latest:

Dr Sonpavde on OS Data With Ipilimumab/Nivolumab in Previously Untreated, Advanced Urothelial Carcinoma

Guru P. Sonpavde, MD, details overall survival data with ipilimumab/nivolumab vs gemcitabine/platinum in previously untreated, advanced urothelial cancer.

Guru Sonpavde, MD

Latest:

Challenges in Standardizing ctDNA-guided MRD Testing in MIBC

Explore the challenges and advancements in ctDNA-based testing for cancer care, focusing on personalized approaches and sensitivity in diverse tumor types.

Gustavo Fernandez, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Gustavo Olivera PhD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Guy Jerusalem, MD, PhD

Latest:

Dr. Jerusalem on Trastuzumab Deruxtecan in HER2+ Breast Cancer

Guy Jerusalem, MD, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Latest:

Dr. Young on the Challenges of Using Anticoagulants in Children With Cancer

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.